Results 161 to 170 of about 260,886 (316)

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis

, 2018
Chang-Liang Luo,1,* Zhi-Gao Xu,2,* Hao Chen,2 Jia Ji,1 Yu-Hui Wang,1 Wei Hu,1 Kun Wang,3 Wu-Wen Zhang,1 Chun-Hui Yuan,4 Fu-Bing Wang1 1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of Pathology ...
Zhang WW, Hu W, Luo CL, Yuan CH, Wang FB, Ji J, Chen H, Xu ZG, Wang YH, Wang K   +9 more
core  

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

The hsa_circ_0070354/miR-4322/RAB3B Axis Facilitates the Carcinogenesis and Development of Non-Small Cell Lung Cancer (NSCLC). [PDF]

Cancer Med
Huang Y, Qin S, Zhang Y, Gu X, Zheng M, Ling G, Yang L, Ju S.   +7 more
europepmc   +1 more source

Variant‐Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs

International Journal of Cancer, EarlyView.
Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens, Jan‐Patrick Hetzel, Khaldoon Abdullah, Carolien Eggermont, Catharina Olsen, Marco Mernberger, Ken Maes, Jelle Vlaeminck, Rainer Claus, Dries Vanisterbecq, Frederik Hes, Martin Pichler, Philippe Giron, Oleg Timofeev, Maxim Noeparast   +14 more
wiley   +1 more source

Role of pleural invasion in non-small cell lung cancer: therapeutic implications and long-term prognosis. [PDF]

openScenario: Nel panorama del trattamento dello stadio clinico I del Tumore polmonare non a piccole cellule degli ultimi decenni, la chirurgia ha svolto un ruolo chiave nella terapia, con l’emergere di due diverse tecniche (segmentectomia, sia anatomica,
MORO, ALESSANDRA
core  

Lung Cancer Patients Display Increased Expression of Bovine Meat and Milk Factor (BMMF) Proteins in Peritumor Alveolar Macrophages

International Journal of Cancer, EarlyView.
Plasmid‐like DNA sequences frequently found in bovine milk and serum have been proposed as infectious agents promoting indirect carcinogenesis. This multi‐omics study detected immune cells positive for these bovine meat and milk factors (BMMFs) in patients with lung cancer, with BMMF expression inversely correlated with smoking intensity.
Nives Cecere, Kristina Alikhanyan, Claudia Ernst, Lisa Häfele, Lars Feuerbach, Imke Grewe, Sumen Siqin, Karin Gunst, Gunjan Shukla, Veronika Frehtman, Claudia Tessmer, Florian Eichhorn, Michael Allgäuer, Alexander Brobeil, Ilse Hofmann, Barbara Leuchs, Marc A. Schneider, Timo Bund   +17 more
wiley   +1 more source

Effect of Perioperative Factors on Short-Term Outcomes in Patients with Non-Small Cell Lung Cancer Over 60 Years of Age

International Journal of General Medicine
Wenzhi Zhu,1,* Jiaonan Yang,1,* Xiaoyi Wang,2 Xinqiang Ji,2 Hongyu Tan1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Anesthesiology, Peking University Cancer Hospital & Institute ...
Zhu W, Yang J, Wang X, Ji X, Tan H
doaj  

DIAGNOSIS AND THERAPY FOR PATIENTS WITH RARE HISTOLOGICAL SUBTYPES OF NON-SMALL CELL LUNG CANCER (NSCLC): A MONOCENTRIC OBSERVATIONAL RETROSPECTIVE STUDY

reservedPresupposti dello studio. Secondo i dati pubblicati dalla WHO nel 2021, solo il 5% dei casi di NSCLC avanzati sono riconducibili a istotipi tumorali rari, intesi come tutte quelle entità istologiche appartenenti ai NSCLC ad eccezione di ...
FOGLIA, LISA
core  

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

<i>AXL</i>-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer. [PDF]

Cancers (Basel)
Ntzifa A, Themistokli E, Strati A, Zavridou M, Tsaroucha E, Sfika A, Psyrri A, Balgouranidou I, Kotsakis A, Georgoulias V, Lianidou E.   +10 more
europepmc   +1 more source